REXULTI® (Brexpiprazole) FDA Approved for Treating Agitation in Alzheimer's Disease Patients
Por um escritor misterioso
Descrição
REXULTI® (brexpiprazole) has been approved by the FDA for treating agitation associated with dementia due to Alzheimer's disease, making it the first and only pharmacological treatment for this indication in the US.
REXULTI® (brexpiprazole) For Healthcare Professionals
FDA approves Lundbeck and Otsuka's agitation treatment for
FDA Approves Rexulti for Agitation Associated With Dementia Due to
FDA Approves First Drug Meant to Ease Alzheimer's-Linked Agitation
FDA OKs First Drug for Agitation in Alzheimer's Dementia
FDA approves new drug for Alzheimer's-Associated agitation
FDA advisors to weigh use of Rexulti for Alzheimer's agitation
FDA approves first drug to treat agitation symptoms associated
SLU Researcher Finds Help for Alzheimer's-Associated Agitation
de
por adulto (o preço varia de acordo com o tamanho do grupo)
